Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
VAC Protocol for Dogs with Stage III Hemangiosarcoma
Hemangiosarcomas (HSAs) are aggressive tumors with a high rate of metastasis. Clinical stage has been considered a negative prognostic factor for survival. The study authors hypothesized that the median survival time (MST) of dogs with metastatic (stage III) HSA treated with a vincristine, doxorubicin, and cyclophosphamide (VAC) chemotherapy protocol would not be different than those with stage I/II HSA. Is this correct?

Sixty-seven dogs with HSA in different anatomic locations were evaluated retrospectively.

All dogs received the VAC protocol as an adjuvant to surgery (n = 50), neoadjuvant (n = 3), or as the sole treatment modality (n = 14).

There was no significant difference (P = 0.97) between the MST of dogs with stage III and stage I/II HSA.

For dogs presenting with splenic HSA alone, there was no significant difference between the MST of dogs with stage III and stage I/II disease (P = 0.12).

The overall response rate (complete response [CR] and partial response [PR]) was 86%).

No unacceptable toxicities were observed.

Dogs with stage III HSA treated with the VAC protocol have a similar prognosis to dogs with stage I/II HSA.

Dogs with HSA and evidence of metastases at the time of diagnosis should not be denied treatment.



Source: Francisco J. Alvarez, Kenji Hosoya, Ana Lara-Garcia, William Kisseberth, Guillermo Couto (2013): VAC Protocol for Treatment of Dogs with Stage III Hemangiosarcoma
In: Published online before print September 19, 2013, doi: 10.5326/JAAHA-MS-5954 Journal of the American Animal Hospital Association Nov/Dec 2013 jaaha.5954






Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Patient-specific facemask to facilitate brain biopsymembers
The objective of this pilot study was to describe the application and first preliminary data of a novel MRI and CT compatible patient-specific facemask for stereotactic brain biopsy of intracranial lesions in dogs. Five client-owned dogs presenting for neurological deficits consistent with forebrain disease were included in the study. All dogs had MRI findings consistent with an intracranial lesion. But biopsies in this region are not easy to obtain. Does an individual face mask help?

  • RET-He to diagnose iron-deficient erythropoiesis in dogsmembers
  • Hypertriglyceridemia-Associated Proteinuria in Miniature Schnauzersmembers
  • Gastrointestinal dysmotility disorders in critically ill animalsmembers
  • Disorder of sex development in a cat with chromosome mosaicism members
  • Generalized discoid lupus erythematosus in dogs members
  • Epidermolysis bullosa acquisita in dogsmembers
  • Chiari-Like Malformation and Syringomyelia in American Brussels Griffon Dogsmembers
  • Efficacy and Potential Complications of Transjugular Liver Biopsymembers
  • Hypomagnesemia in Brachycephalic Dogsmembers
  • Comparison of two minimally invasive techniques for liver biopsy members
  • Topical aqueous sirolimus and the tear production members
  • JAK 1/2 inhibitor in the treatment of canine B-cell lymphomamembers


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved